Novocure Ltd. (NVCR) News
Filter NVCR News Items
NVCR News Results
|Loading, please wait...|
NVCR News Highlights
- NVCR's 30 day story count now stands at 7.
- Over the past 28 days, the trend for NVCR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ROOT, NOV and TOP are the most mentioned tickers in articles about NVCR.
Latest NVCR News From Around the Web
Below are the latest news stories about NOVOCURE LTD that investors may wish to consider to help them evaluate NVCR as an investment opportunity.
In this piece, we will take a look at the 15 best falling stocks to buy now. If you want to skip our overview of the current stock market environment and our coverage of the latest stock market news, then you can skip ahead to 5 Best Falling Stocks To Buy Now. With 2023 coming […]
Top performing stocks in 2023 included those in the technology sector, taking advantage of developments in AI. The bottom performers included NVCR, which was punished because of its ovarian cancer trials' failure to improve survival rates in patients.
Rivian stock is getting a boost on Tuesday after analysts at Evercore ISI weighed in on RIVN shares with a reiterated outperform rating.
FuelCell Energy stock is climbing higher on Tuesday as investors in FCEL celebrate the company signing a deal with IBM!
Novocure layoffs are coming for 13% of the company's workers as it seeks to reduce its headcount by 200 people to reduce costs.
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
ROOT, Switzerland, November 28, 2023--Novocure today announced a series of actions to strengthen and optimize business operations to support growth drivers and long-term value creation.
ROOT, Switzerland, November 21, 2023--Novocure announced today that management will participate in the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023.
NovoCure Limited (NASDAQ:NVCR) institutional owners may be pleased with recent gains after 85% loss over the past year
Key Insights Given the large stake in the stock by institutions, NovoCure's stock price might be vulnerable to their...
In this piece, we will take a look at the 11 best undervalued U.K. stocks to buy now. If you want to skip our overview of the British economy, then take a look at 5 Best Undervalued UK Stocks To Buy Now. The U.K. is one of the biggest economies in the world and a […]
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
ROOT, Switzerland, November 10, 2023--Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblastoma (GBM) and other central nervous system tumors (CNS), will be presented at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting from Nov. 16 to Nov. 19 in Vancouver, Canada.